3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lung Neoplasms
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Pheochromocytoma
1
Paraganglioma
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Ductal Adenocarcinoma
1
Osteoradionecrosis
1
Mouth Neoplasms
1
Melanoma
1
Hereditary leiomyomatosis and renal cell cancer
1
Gliosarcoma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Craniopharyngioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Temozolomide
40
Magnetic Resonance Spectroscopy
19
Radiotherapy
18
Specimen Handling
14
Radiation
12
Bevacizumab
11
Lomustine
9
pembrolizumab
6
fludarabine
5
Surgical Procedures, Operative
5
atezolizumab
4
Nivolumab
4
Ipilimumab
4
Cyclophosphamide
4
Carboplatin
4
Biopsy
4
cemiplimab
3
azeliragon
3
Immunoglobulin G
3
Disulfides
3
Aminolevulinic Acid
3
veliparib
2
trametinib
2
rocakinogene sifuplasmid
2
poly ICLC
2
olaparib
2
lutetium Lu 177 dotatate
2
durvalumab
2
dabrafenib
2
contrast agent BR1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Glioblastoma
×
Contrast Media
×
90 days
×
Clear all
No trials found.